Floatz Rating
B57/100
Confidence
Indicative
Sponsor
National University Hospital, Singapore
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05381038CT.gov Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | — | Recruiting | — | — | — |
NCT04553692CT.gov Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | — | Terminated | — | — | — |
NCT03814005CT.gov A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems | — | Completed | — | — | — |
NCT03614728CT.gov Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT02959437CT.gov Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | — | Terminated | — | — | — |
NCT02711137CT.gov Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | — | Terminated | — | — | — |
NCT02587598CT.gov Study of INCB053914 in Subjects With Advanced Malignancies | — | Terminated | — | — | — |
NCT02223052CT.gov Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | — | Completed | — | — | — |
NCT02265510CT.gov An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT01537744CT.gov A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma | — | Completed | — | — | — |
Show 4 more trialsShow fewer
NCT00652626CT.gov Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function | — | Completed | — | — | — |
NCT00996515CT.gov A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies | — | Completed | — | — | — |
NCT00529022CT.gov Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer | — | Completed | — | — | — |
NCT00741234CT.gov A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Azacitidine (this asset) | National University Hospital, Singapore | P1/2 | B · 57 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Azacitidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 73 |
| Acute Erythroid Leukemia | — | P2 | BB · 71 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Azacitidine in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/azacitidine-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →